Alternation in glucagon secretion associated with progression of glucose intolerance.

Alternation in glucagon secretion associated with progression of glucose intolerance. - Glucagon secretion and progression of glucose intolerance.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016133

Enrollment

Registered

2015-01-06

Start date

2014-12-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

normal glucose tolerance, impaired glucose metabolism, Type 2 diabetes mellitus (non-insulin dependent)

Interventions

normal glucose tolerance(fasting plasma glucose &lt

110mg/dl(6.1mmol/l) and 2h-plasma glucose &lt

140mg/dl(7.8mmol/l))at 75g oral glucose tolerance test. impaired fasting glucose (fasting plasma glucose 110-126mg/dl(6.1-7.7mmol/l)), and/or impaired glucose tolerance (2h-plasma glucose 140-200m

=126mg/dl(7.7mmol/l) and/or 2h-plasma glucose &gt

=200mg/dl(11.1mmol/l) at 75g oral glucose tolerance test

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Type 2 (non-insulin dependent) diabetes subjects who are well-controlled in diet and exercise. 2. Patients undergo 75g oral glucose tolerance test to examine glucose tolerance. 3. Normal healthy volunteers.

Exclusion criteria

Exclusion criteria: 1. A patient suffering from acute disease 2. In case of malignacy 3. Renal dysfunction (estimeted GFR <60ml/min) 4. Liver dysfunction (AST >100U/l, ALT >100U/l) 5. Pregnant or possibility of pregnant 6. Lactating mothers 7. A patient suffering from endocrine disorders 8. A patient administrated any drugs affect glucose metabolism 9. Diabetic patients who need any hypoglycemic agents 10. Fasting plasma glucose >=140mg/dl (7.8mmol/l) 11. Casual plasma glucose >=200mg/dl (11.1mmol/l) 12. Glycated hemoglobin (HbA1c) >=7.5%

Design outcomes

Primary

Measure	Time frame
Compare the difference in alteration of glucagon secretion in oral glucose tolerance test between normal glucose tolerance, impaired glucose metabolism and type 2 diabetes mellitus (non-insulin dependent).	—

Countries

Japan

Contacts

Public ContactRaishi Ichikawa

Kitasato University School of Medicine Departmet of endocrinology, diabetes & metabolism

raizo@med.kitasato-u.ac.jp042-778-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026